Normative Issues in Next Generation Sequencing Gene Testing
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Despite the commercialization of Next generation sequencing (NGS) gene testing, only a few studies have addressed the various ethical and legal problems associated with NGS testing in Korea Here, we reviewed the normative issues that emerged at each stage of the wet analysis and bioinformatics analysis of NGS gene testing. In particular, it was in mind to apply various international guidelines and the principles of bioethics to actual clinical practice. Considering the characteristics of NGS testing, wet analysis of additional testing can be justified if presumptive consent is recognized. Furthermore, the medical relationship between diseases needs to be established and it should be clear that the patient would have given consent if the patient had been aware of the correlation between genes. At the stage of bioinformatics analysis, the question of unsolicited findings arises. In case of unsolicited and relevant findings, according to American College of Medical Genetics and Genomics (ACMG), a recognized relationship between genes and diseases needs to be established. In case of unsolicited and not-relevant findings, it is almost impossible to determine whether knowing or not knowing the findings is more beneficial to the patient. However, it seems to be certain that the psychological harm an individual may suffer from such information is likely to be greater if the disease is severe and if there is no cure. The list of genes for which the ACMG guidelines impose reporting obligations is a good reference for judgment.
Abstract
Despite the commercialization of Next generation sequencing (NGS) gene testing, only a few studies have addressed the various ethical and legal problems associated with NGS testing in Korea Here, we reviewed the normative issues that emerged at each stage of the wet analysis and bioinformatics analysis of NGS gene testing. In particular, it was in mind to apply various international guidelines and the principles of bioethics to actual clinical practice. Considering the characteristics of NGS testing, wet analysis of additional testing can be justified if presumptive consent is recognized. Furthermore, the medical relationship between diseases needs to be established and it should be clear that the patient would have given consent if the patient had been aware of the correlation between genes. At the stage of bioinformatics analysis, the question of unsolicited findings arises. In case of unsolicited and relevant findings, according to American College of Medical Genetics and Genomics (ACMG), a recognized relationship between genes and diseases needs to be established. In case of unsolicited and not-relevant findings, it is almost impossible to determine whether knowing or not knowing the findings is more beneficial to the patient. However, it seems to be certain that the psychological harm an individual may suffer from such information is likely to be greater if the disease is severe and if there is no cure. The list of genes for which the ACMG guidelines impose reporting obligations is a good reference for judgment.
참고문헌 (34)
- ACMG, "ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing", Genetics in Medicine, 15(7) (2013)
- ACMG, "ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)", Genetics in Medicine, 24, pp.1407~1414 (2022)
- BGHZ, "Entscheidungen des Bundesgerichtshofes in Zivilsachen", Bundesgerichtshof, 107~ (1989)
- Bortolotti L, "The right not to know: The case of psychiatric disorders", J Med Ethics, 37, pp.673~676 (2011)
- Chadwick R, "The Right to Know and the Right Not to Know: Genetic Privacy and Responsibility" (2014), Cambridge University Press
- Creighton S, "Predictive, pre-natal and diagnostic genetic testing for Huntington’s disease: The experience in Canada from 1987 to 2000", Clin Genet, 63, pp.462~475 (2003)
- Deutscher Ethikrat, "Die Zukunft der genetischen Diagnostik von der Forschung in die klinischen Anwendung", Jahr Wiss Ethik, 18, pp.173~A7 (2013)
- Egalite N, "Genetic counseling practice in next generation sequencing research: Implications for the ethical oversight of the informed consent process", J Genet Couns, 23, pp.661~670 (2014)
- EuroGentest, "Guidelines for diagnostic next generation sequencing", European Journal of Human Genetics, 24, pp.2~5 (2016)
- Facio FM, "A genetic counselor’s guide to using next-generation sequencing in clinical practice", J Genet Couns, 23, pp.455~462 (2014)
- Fecteau H, "The evolution of cancer risk assessment in the era of next generation sequencing", J Genet Couns, 23, pp.633~639 (2014)
- Feinberg J, "Philosophy of Education:An Anthology", pp.112~123 (2006), Blackwell
- Gadamer HG, "Über die Verborgenheit der Gesundheit", Erfahrungsheilkunde, 52, pp.644~649 (2010)
- Gallego CJ, "Next generation sequencing in the clinic: A patterns of care study in a retrospective cohort of subjects referred to a genetic medicine clinic for suspected lynch sSyndrome", J Genet Couns, 25, pp.515~519 (2016)
- GEKO, "RL-GEKO für die Beurteilung genetischer Eigenschaften hinsichtlich ihrer Bedeutung für Erkrankungen oder gesundheitliche Störungen sowie für die Möglichkeiten, siezu vermeiden, ihnen vorzubeugen oder sie zu behandeln gemäß §23 Abs.2 Nr.1a GenDG", Bundesgesundheitsblatt, 56, pp.159~162 (2013)
- Habermas J, "Theorie des kommunikativen Handelns. Bd.1 & Bd.2" (2011), Suhrkamp Verlag
- Huang JT, "The ophthalmic experience: Unanticipated primary findings in the era of next generation sequencing", J Genet Couns, 23, pp.588~593 (2014)
- Kant I, "Beantwortung der Frage: Was ist Aufklärung?" (2011), Amazon Media EU
- 김나경, "의사의 설명의무의 법적 이해", 한국의료법학회지, 15(1), pp.7~28 (2007), 한국의료법학회
- 김나경, "장애 이해의 해석학적 구조화와 법: 생명윤리안전법상 유전자검사 규율의 방향 모색", 생명윤리, 16(2), pp.67~84 (2015), 한국생명윤리학회
- Kim Na-Kyoung, "A Case of Next-generation Sequencing Gene Testing: Points to be Considered in Testing and Reporting", Annals of Laboratory Medicine, 42(2), pp.296~297 (2022), 대한진단검사의학회[DOI]
- Knoll AM, "The reawakening of complementary and alternative medicine at the turn of the twenty-first century: Filling the void in conventional biomedicine", J Contemp Health Law Policy, 20, pp.329~366 (2003)
- "Korean Supreme Court (1994) 94 da 35671 (Nov. 25, 1994, decided)", ~ (1994)
- "Korean Supreme Court (1994) 92 da 25885 (Apr. 15, 1994, decided)", ~ (1994)
- "Korean Supreme Court (2002) 2001 da 27449 (Jan. 11, 2002, decided)", ~ (2002)
- "Korean Supreme Court (2007) 2005 da 69540 (Sep. 7, 2007, decided)", ~ (2007)
- "Korean Supreme Court (2015) 2014 da 22871 (Oct. 29, 2015, decided)", ~ (2015)
- McGuire AL, "Ethics and genomic incidental findings: Laboratories have an obligation to report clinically beneficial incidental findings", Science, 340, pp.1047~1048 (2013)
- Meiser B, "Acceptability of, and information needs regarding, next-generation sequencing in people tested for hereditary cancer: A qualitative study", J Genet Couns, 25, pp.218~227 (2016)
- O’Neill O, "Autonomy and Trust in Bioethics" (2002), Cambridge University Press
- O’Neill O, "Rethinking Informed Consent in Bioethics" (2008), Cambridge University Press
- "Texas Supreme Court (1983) Peterson v. Shields, 652 S.W.2d 929 (Tex.)", ~ (1983)
- Wachsmuth W, "Der unheilvolle Weg in die defensive Medizin: Reden und Aufsätze 1930–1984", pp.180~188 (1985), Springerverlag
- Yi SD, "Medical Law" (2017), Bubmoon